Collegium Infringing OxyContin Patents, Purdue Says
Law360, New York (October 6, 2017, 5:36 PM EDT) -- Collegium Pharmaceutical Inc. is infringing two of Purdue Pharma LP's patents tied to the opioid painkiller OxyContin when making and selling its painkiller Xtampza ER, Purdue alleged on Friday in Massachusetts federal court, as part of a long line of similar suits.
In its supplemental New Drug Application, Collegium certified that it wasn’t infringing any of Purdue’s patents, but Purdue is arguing otherwise, saying the competitor is infringing U.S. Patent Numbers 9,522,919 and 9,073,933. This is the seventh suit that Purdue has filed against Collegium over extended release Xtampza, citing infringement of eight patents total.
The U.S. Food and Drug Administration...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!